Follow-On Biologics Guidance Delay Lauded By Senate Health Cmte. Staffer
Executive Summary
FDA should not issue a guidance on follow-on biologics until after Congress has established a regulatory pathway, Senate Health Committee Counsel Steve Irizarry said at an American Conference Institute meeting in New York June 25
You may also be interested in...
FDA Follow-On Biologics Public Meeting Slated For Early ’05
FDA and the Drug Information Association are looking at dates in early 2005 for a public meeting on scientific issues surrounding the development of follow-on biologics
FDA Follow-On Biologics Public Meeting Slated For Early ’05
FDA and the Drug Information Association are looking at dates in early 2005 for a public meeting on scientific issues surrounding the development of follow-on biologics
Follow-On Biologics Process May Allow Post-Approval Immunogenicity Tests
A regulatory process for follow-on biologics could allow for post-approval immunogenicity testing, FDA Office of Biotechnology Products Principal Advisor for Regulatory Science & Review Anthony Mire-Sluis, PhD, suggested